Drug-Related Pneumonitis in Cancer Treatment during the COVID-19 Era
Interstitial lung disease is recognized as a group of diseases with a different etiopathogenesis characterized by chronic lung inflammation with the accumulation of inflammatory cells, lymphocytes and macrophages, and the consequent release of proinflammatory cytokines. Various degrees of pulmonary...
Main Authors: | Sara Cherri, Silvia Noventa, Martina Fanelli, Giulio Calandra, Tiziana Prochilo, Claudio Bnà, Giordano Savelli, Alberto Zaniboni |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/5/1052 |
Similar Items
-
PEDIATRIC HYPERSENSITIVE PNEUMONITIS POSITIVE EXPERIENCE IN MANAGEMENT
by: N. S. LEV, et al.
Published: (2017-07-01) -
Paclitaxel-induced acute fibrinous and organizing pneumonitis in early breast cancer: A case report
by: Piyarat Limpawittayakul, et al.
Published: (2024-01-01) -
Challenges in the Diagnosis and Management of Fibrotic Hypersensitivity Pneumonitis: A Practical Review of Current Approaches
by: Teng Moua, et al.
Published: (2022-03-01) -
Hypersensitivity pneumonitis: an overlooked cause of cough and dyspnea
by: Ryan S. D’souza, et al.
Published: (2017-04-01) -
Impact of radiographic honeycombing on transplant free survival and efficacy of immunosuppression in fibrotic hypersensitivity pneumonitis
by: Traci N. Adams, et al.
Published: (2023-06-01)